Rigontec GmbH CEO Dr. Christian Schetter explains to Mike Ward, Informa Pharma Insights global director of content, how his company is developing a new class of RNA-based immunotherapeutics to treat cancers and viral diseases by targeting RIG-I, one of the essential pathways of the innate immune system. Rigontec's proprietary agonists are designed to activate RIG-I specifically, inducing both immediate and long-term anti-tumor immunity, and achieving substantial local and systemic tumor regression in several relevant in vivo models.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
